Press Releases + New Year: - Any -2024202320222021202020192018201720162015201420132012201120102009 Items per page 102550 Date Title and Summary View Toggle SummaryMar 22, 2012 Galectin Therapeutics Inc. Announces Pricing of Public Offering of 1,159,445 Units, Listing on Nasdaq and Effectiveness of Reverse Stock Split View HTML Galectin Therapeutics Inc. Announces Pricing of Public Offering of 1,159,445 Units, Listing on Nasdaq and Effectiveness of Reverse Stock Split 18.7 KB Toggle SummaryMar 05, 2012 Galectin Therapeutics Inc. Appoints Thomas A. McGauley as Acting Chief Financial Officer and Extends Term of Employment of Maureen E. Foley as Chief Operating Officer View HTML Galectin Therapeutics Inc. Appoints Thomas A. McGauley as Acting Chief Financial Officer and Extends Term of Employment of Maureen E. Foley as Chief Operating Officer 15.8 KB Toggle SummaryFeb 09, 2012 Galectin Therapeutics to Present Corporate Update at BIO CEO & Investor Conference View HTML Galectin Therapeutics to Present Corporate Update at BIO CEO & Investor Conference 15.6 KB Toggle SummaryDec 19, 2011 Galectin Therapeutics Provides Corporate Update View HTML Galectin Therapeutics Provides Corporate Update 25 KB Toggle SummaryDec 16, 2011 Galectin Therapeutics Presents Preclinical Data on the Treatment of Fatty Liver Disease and Fibrosis at EASL View HTML Galectin Therapeutics Presents Preclinical Data on the Treatment of Fatty Liver Disease and Fibrosis at EASL 16.5 KB Toggle SummaryDec 08, 2011 Novel Cancer Treatment Combination Receives Approval to Begin First-in-Human Testing for Patients with Advanced Metastatic Melanoma Trial to Evaluate the Safety and Efficacy of Immunomodulatory Compound, GM-CT-01, with Peptide Vaccine View HTML Novel Cancer Treatment Combination Receives Approval to Begin First-in-Human Testing for Patients with Advanced Metastatic Melanoma 21.2 KB Toggle SummaryNov 10, 2011 Galectin Therapeutics Reports Third Quarter and Nine Months 2011 Financial Results View HTML Galectin Therapeutics Reports Third Quarter and Nine Months 2011 Financial Results 19 KB Toggle SummaryNov 02, 2011 Galectin Therapeutics Announces Formation of Liver Fibrosis Clinical Trials Advisory Board View HTML Galectin Therapeutics Announces Formation of Liver Fibrosis Clinical Trials Advisory Board 16.9 KB Toggle SummaryOct 13, 2011 Galectin Therapeutics to Announce New Data on the Treatment of Fatty Liver Disease and Fibrosis -- Abstract Accepted for Presentation at the European Association for Study of the Liver Special Conference on Liver Transplantation -- View HTML Galectin Therapeutics to Announce New Data on the Treatment of Fatty Liver Disease and Fibrosis 15.5 KB Toggle SummaryOct 12, 2011 Galectin Therapeutics Elects Dr. Marc Rubin to its Board of Directors View HTML Galectin Therapeutics Elects Dr. Marc Rubin to its Board of Directors 15.8 KB Pagination First page First Previous page Previous … Page 30 Current page 31 Page 32 Page 33 … Next page Next Last page Last
Galectin Therapeutics Inc. Announces Pricing of Public Offering of 1,159,445 Units, Listing on Nasdaq and Effectiveness of Reverse Stock Split 18.7 KB
Galectin Therapeutics Inc. Appoints Thomas A. McGauley as Acting Chief Financial Officer and Extends Term of Employment of Maureen E. Foley as Chief Operating Officer 15.8 KB
Galectin Therapeutics Presents Preclinical Data on the Treatment of Fatty Liver Disease and Fibrosis at EASL 16.5 KB
Novel Cancer Treatment Combination Receives Approval to Begin First-in-Human Testing for Patients with Advanced Metastatic Melanoma 21.2 KB
Galectin Therapeutics to Announce New Data on the Treatment of Fatty Liver Disease and Fibrosis 15.5 KB
